Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study

被引：15

作者：

Burger, Robert Allen

Enserro, Danielle

Tewari, Krishnansu Sujata

Brady, Mark F.

Bookman, Michael A.

Fleming, Gini F.

Huang, Helen Q.

Homesley, Howard D.

Fowler, Jeffrey

Boente, Matthew

Randall, Leslie M.

Chan, John K.

Ferris, James Stuart

DiSaia, Philip J.

Copeland, Larry J.

Mannel, Robert S.

Birrer, Michael J.

Monk, Bradley J.

机构：

[1] Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA

[2] NRG Oncol, Buffalo, NY USA

[3] Univ Calif Irvine, Div Gynecol Oncol, Irvine, CA USA

[4] Roswell Park Canc Inst, NRG Stat & Data Ctr, Buffalo, NY 14263 USA

[5] Univ Arizona, Tucson, AZ 85721 USA

[6] Univ Chicago, Chicago, IL 60637 USA

[7] GOG Stat & Data Ctr, Rochester, NY USA

[8] Brody Sch Med, Greenville, NC USA

[9] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA

[10] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

[11] Univ Calif Irvine, Orange, CA 92668 USA

[12] Palo Alto Med Fdn, San Francisco, CA USA

[13] Univ Med Ctr, Breckenridge Shivers Ctr, Austin, TX USA

[14] Univ Calif Irvine, Med Ctr, Orange, CA USA

[15] James Canc Hosp, Columbus, OH USA

[16] Stephenson Canc Ctr, Oklahoma City, OK USA

[17] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA

[18] Univ Arizona Canc Ctr Dignity Hlth, St Josephs Hosp & Med Ctr, Phoenix, AZ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.5517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5517

引用

页数：2